{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T09:53:42Z","timestamp":1649152422361},"reference-count":34,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.3892\/ol.2015.2855","type":"journal-article","created":{"date-parts":[[2015,1,7]],"date-time":"2015-01-07T04:00:31Z","timestamp":1420603231000},"page":"1059-1064","source":"Crossref","is-referenced-by-count":0,"title":["TEGAFIRI is an effective alternative regimen for the management of recurrent or metastatic colorectal cancer"],"prefix":"10.3892","volume":"9","author":[{"given":"TZU-CHI","family":"HSU","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2015,1,7]]},"reference":[{"key":"key20180108102634_b1-ol-09-03-1059","first-page":"3867","article-title":"A phase II study of weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin (HDFL) in the treatment of recurrent or metastatic colorectal cancers","volume":"17","author":"Yeh","year":"1997","journal-title":"Anticancer Res"},{"key":"key20180108102634_b2-ol-09-03-1059","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1179\/joc.2000.12.2.183","article-title":"Phase II study of weekly high-dose fluorouracil in previously treated patients with metastatic colorectal cancer","volume":"12","author":"Mermershtain","year":"2000","journal-title":"J Chemother"},{"key":"key20180108102634_b3-ol-09-03-1059","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(98)02309-5","article-title":"Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patient with metastatic colorectal cancer","volume":"352","author":"Cunningham","year":"1998","journal-title":"Lancet"},{"key":"key20180108102634_b4-ol-09-03-1059","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","article-title":"Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomized trial","volume":"355","author":"Douillard","year":"2000","journal-title":"Lancet"},{"key":"key20180108102634_b5-ol-09-03-1059","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/(SICI)1097-0142(19990215)85:4<786::AID-CNCR5>3.0.CO;2-9","article-title":"A multicenter phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma","volume":"85","author":"Rothenberg","year":"1999","journal-title":"Cancer"},{"key":"key20180108102634_b6-ol-09-03-1059","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1023\/A:1008478405634","article-title":"A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer","volume":"9","author":"Van Cutsem","year":"1998","journal-title":"Ann Oncol"},{"key":"key20180108102634_b7-ol-09-03-1059","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/BF00254241","article-title":"Report on nationwide-pooled data and cohort investigation in UFT phase II study","volume":"22","author":"Ota","year":"1988","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20180108102634_b8-ol-09-03-1059","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1634\/theoncologist.7-4-288","article-title":"Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review","volume":"7","author":"Malet-Martino","year":"2002","journal-title":"Oncologist"},{"key":"key20180108102634_b9-ol-09-03-1059","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/1097-0142(20000915)89:6<1228::AID-CNCR6>3.0.CO;2-O","article-title":"Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases","volume":"89","author":"Kusunoki","year":"2000","journal-title":"Cancer"},{"key":"key20180108102634_b10-ol-09-03-1059","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/annonc\/mdg340","article-title":"A phase I\/II study of oral uracil\/tegafur (UFT), leucovorin, and irinotecan in patients with advanced colorectal cancer","volume":"14","author":"Mackay","year":"2003","journal-title":"Ann Oncol"},{"key":"key20180108102634_b11-ol-09-03-1059","first-page":"2673","article-title":"Phase I\/II study of irinotecan and UFT for advanced or metastatic colorectal cancer","volume":"27","author":"Mibu","year":"2007","journal-title":"Anticancer Res"},{"key":"key20180108102634_b12-ol-09-03-1059","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/sj.bjc.6603493","article-title":"Uracil\/ftorafur\/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patient: results of randomized phase II study","volume":"96","author":"Bajetta","year":"2007","journal-title":"Br J Cancer"},{"key":"key20180108102634_b13-ol-09-03-1059","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/sj.bjc.6603889","article-title":"Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer","volume":"97","author":"Delord","year":"2007","journal-title":"Br J Cancer"},{"key":"key20180108102634_b14-ol-09-03-1059","first-page":"475","article-title":"Metronomic chemotherapy using weekly low-dosage CPT-11 and UFT as postoperative adjuvant therapy in colorectal cancer at high risk to recurrence","volume":"26","author":"Ogata","year":"2007","journal-title":"J Exp Clin Cancer Res"},{"key":"key20180108102634_b15-ol-09-03-1059","first-page":"254","article-title":"Combination chemotherapy with irinotecan and oral uracil-tegafur for recurrent or metastatic colorectal cancer - results of different regimens","volume":"25","author":"Hsu","year":"2009","journal-title":"J Chinese Oncol Soc"},{"key":"key20180108102634_b16-ol-09-03-1059","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"key20180108102634_b17-ol-09-03-1059","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JCO.1984.2.3.187","article-title":"Karnofsky performance status revisited: reliability, validity, and guidelines","volume":"2","author":"Schag","year":"1984","journal-title":"J Clin Oncology"},{"key":"key20180108102634_b18-ol-09-03-1059","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/jcp.2.2.95","article-title":"The surgical pathology of rectal cancer","volume":"2","author":"Dukes","year":"1949","journal-title":"J Clin Pathol"},{"key":"key20180108102634_b19-ol-09-03-1059","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"key20180108102634_b20-ol-09-03-1059","unstructured":"Cancer Therapy Evaluation ProgramCommon Toxicity Criteria, Version 2.0April301999http:\/\/prevention.cancer.gov\/files\/clinical-trials\/common-toxicity-criteria.pdfAccessed November 22, 2014"},{"key":"key20180108102634_b21-ol-09-03-1059","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3322\/canjclin.54.1.8","article-title":"American Cancer Society: Cancer statistics, 2004","volume":"54","author":"Jemal","year":"2004","journal-title":"CA Cancer J Clin"},{"key":"key20180108102634_b22-ol-09-03-1059","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3322\/canjclin.49.1.33","article-title":"Global cancer statistics","volume":"49","author":"Parkin","year":"1999","journal-title":"CA Cancer J Clin"},{"key":"key20180108102634_b23-ol-09-03-1059","unstructured":"Colorectal CancerEstimated Incidence, Mortality and Prevalence Worldwide in 2012GLOBOCAN2012http:\/\/globocan.iarc.fr\/old\/FactSheets\/cancers\/colorectal-new.aspAccessed November 22, 2014"},{"key":"key20180108102634_b24-ol-09-03-1059","unstructured":"Colorectal Cancer Facts & Figures 2014\u20132016American Cancer Society2014http:\/\/www.cancer.org\/acs\/groups\/content\/documents\/document\/acspc-042280.pdfAccessed November 22, 2014"},{"key":"key20180108102634_b25-ol-09-03-1059","first-page":"437","volume-title":"Cancer Principles and Practice of Oncology","author":"DeVita","year":"1997","edition":"5th edition"},{"key":"key20180108102634_b26-ol-09-03-1059","first-page":"377","article-title":"Studies on coadministration of uracil or cytosine on antitumor activity of FT-207 or 5-FU derivatives","volume":"6","author":"Fujii","year":"1979","journal-title":"Jpn J Cancer Chemother"},{"key":"key20180108102634_b27-ol-09-03-1059","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1200\/JCO.2002.04.123","article-title":"Multicenter phase III study of uracil\/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer","volume":"20","author":"Douillard","year":"2002","journal-title":"J Clin Oncol"},{"key":"key20180108102634_b28-ol-09-03-1059","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2165\/00003495-199958003-00011","article-title":"Tegafur\/uracil + calcium folinate in colorectal cancer: double modulation of fluorouracil","volume":"58","author":"Hoff","year":"1999","journal-title":"Drugs"},{"issue":"10 Suppl 9","key":"key20180108102634_b29-ol-09-03-1059","first-page":"13","article-title":"UFT: mechanism of drug action","volume":"14","author":"K\u00f6hne","year":"2000","journal-title":"Oncology (Williston Park)"},{"issue":"10 Suppl 7","key":"key20180108102634_b30-ol-09-03-1059","first-page":"48","article-title":"The oral fluorouracil prodrugs","volume":"12","author":"Pazdur","year":"1998","journal-title":"Oncology (Williston Park)"},{"key":"key20180108102634_b31-ol-09-03-1059","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1200\/JCO.2002.10.129","article-title":"Randomized comparative study of tegafur\/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer","volume":"20","author":"Carmichael","year":"2002","journal-title":"J Clin Oncol"},{"key":"key20180108102634_b32-ol-09-03-1059","first-page":"547","article-title":"The usefulness of pharmacokinetic modulating chemotherapy (UFT plus 5FU) in the treatment of unresectable colorectal carcinomas","volume":"6","author":"Kusunoki","year":"1999","journal-title":"Oncol Rep"},{"key":"key20180108102634_b33-ol-09-03-1059","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/jjco\/hyd124","article-title":"Phase II study of oral tegafur-uracil and folinic acid as first-line therapy for metastatic colorectal cancer: Taiwan experience","volume":"30","author":"Lin","year":"2000","journal-title":"Jpn J Clin Oncol"},{"key":"key20180108102634_b34-ol-09-03-1059","first-page":"298","article-title":"Retrospectively comparative evaluation of the first- and second-line chemotherapy with campto and oxaliplatin combined with oral tegafur\/uracil (UFT)\/leucovorin (LV) in patients with metastatic colorectal cancer","volume":"94","author":"Hsiao","year":"2009","journal-title":"Int Surg"}],"container-title":["Oncology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ol.2015.2855\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T08:18:36Z","timestamp":1515399516000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ol.2015.2855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,7]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,1,7]]},"published-print":{"date-parts":[[2015,3]]}},"alternative-id":["10.3892\/ol.2015.2855"],"URL":"https:\/\/doi.org\/10.3892\/ol.2015.2855","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,7]]}}}